Tools
Tools
Mukhtyar, C. 
ORCID: https://orcid.org/0000-0002-9771-6667, Lee, R., Brown, D., Carruthers, D., Dasgupta, B., Dubey, S., Flossmann, O., Hall, C., Hollywood, J., Jayne, D., Jones, R., Lanyon, P., Muir, A., Scott, D., Young, L. and Luqmani, R. A.
(2009)
Modification and validation of the Birmingham Vasculitis Activity Score (version 3).
Annals of the Rheumatic Diseases, 68 (12).
pp. 1827-1832.
ISSN 0003-4967
Abstract
Background: Comprehensive multisystem clinical assessment using the Birmingham Vasculitis Activity score (BVAS) is widely used in therapeutic studies of systemic vasculitis. Extensive use suggested a need to revise the instrument. The previous version of BVAS has been revised, according to usage and reviewed by an expert committee. Objective: To modify and validate version 3 of the BVAS in patients with systemic vasculitis. Methods: The new version of BVAS was tested in a prospective cross-sectional study of patients with vasculitis. Results: The number of items was reduced from 66 to 56. The subscores for new/worse disease and persistent disease were unified. In 313 patients with systemic vasculitis, BVAS(v.3) correlated with treatment decision (Spearman’s rs = 0.66, 95% CI 0.59 to 0.72), BVAS1 of version 2 (rs = 0.94, 95% CI 0.92 to 0.96), BVAS2 of version 2 in patients with persistent disease (rs = 0.60, 95% CI 0.21 to 0.83), C-reactive protein levels (rs = 0.43, 95% CI 0.31 to 0.54), physician’s global assessment (rs = 0.91, 95% CI 0.89 to 0.93) and vasculitis activity index (rs = 0.88, 95% CI 0.86 to 0.91). The intraclass correlation coefficients for reproducibility and repeatability were 0.96 (95% CI 0.95 to 0.97) and 0.96 (95% CI 0.92 to 0.97), respectively. In 39 patients assessed at diagnosis and again at 3 months, the BVAS(v.3) fell by 17 (95% CI 15 to 19) units (p<0.001, paired t test). Conclusion: BVAS(v.3) demonstrates convergence with BVAS(v.2), treatment decision, physician global assessment of disease activity, vasculitis activity index and C-reactive protein. It is repeatable, reproducible and sensitive to change. The new version of BVAS is validated for assessment of systemic vasculitis.
| Item Type: | Article |
|---|---|
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| Related URLs: | |
| Depositing User: | Rhiannon Harvey |
| Date Deposited: | 27 Apr 2011 15:30 |
| Last Modified: | 15 Mar 2024 12:30 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/29821 |
| DOI: | 10.1136/ard.2008.101279 |
Actions (login required)
 |
View Item |